Similar documents
Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

Fig. 1 Chemical structure of DL-8280


Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Fig. 1 Chemical structure of KW-1070

VOL.42 S-1

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

Fig. 1 Chemical structure of norfioxacin (AM-715)


epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY

CHEMOTHERAPY

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum


coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY

1272 CHEMOTHERAPY MAR. 1975

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )



CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

Fig.1 Chemical structure of BAY o 9867

Table1MIC of BAY o 9867 against standard strains


VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY MAY. 1988

988 CHEMOTHERAPY NOV. 1971

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL. 34 S-2 CHEMOTH8RAPY 913

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -


CHEMOTHERAPY FEB Table 1 Background of volunteers

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1





Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

CHEMOTHERAPY JAN Fig. 1 Structure of cephradine


400 CHEMOTHERAPY JAN Table 1 Cases of drop outs

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.




日本化学療法学会雑誌第65巻第4号

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

CHEMOTHERAPY JUNE 1986


CHEMOTHERAPY SEPT. 1970


CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K


CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)




04-c-„FŒ{›xŒ¾-4.01

日本化学療法学会雑誌第59巻第5号

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

VOL.39 S-3



Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): Issue Date URL

CHEMOT HERAPY

CHEMOTHERAPY


CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

VOL. 36 S-3 CHEMOTHERAPY 437

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

VOL. 43 NO. 4

56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit

Transcription:

Table 1 Classification of female patients with vealcal irritating symptom by their signs Urination pain with other vesical irritability or not

Table 2 Serum levels of DL-8280 after a single oral administration (Mine healthy volunteers and outpatients with urinary tract infections In Sample was not collected. Case No. 1, 2, 3: Volunteers, Case No. 4, 5, 6: Outpatients Table 3-(1) Urinary levels of DL-8280 after a single oral administration (100mg) in healthy volunteers and outpatients with urinary tract infections (1) Urine volume was corrected to 1ml/min. Retention time (min) of urine in bladder Case No. 1, 2: Urine was collected in time schedule. Case No. 3, 4, 5: Urine was collected free. Table 3-(2) Urinary levels of DL-8280 after a single oral administration (100mg) in healthy volunteers and outpatients with urinary tract infections (2) Urine volume was corrected to lml/min. Retention time (min) of urine in bladder

534 CHEMOTHERAPY FEB. 1984 Table 5-(1) Distribution of clinical sings before treatment in cases of Group I

Table 5-(2) Distribution of clinical sings before treatment in cases of Group II

Table 5-(3) Distribution of clinical sings before treatment in cases of Group III

Table 5-(4) Distribution of clinical sings before treatment in cases of Group IV

CHEMOTHERAPY FEB. 1984 Table 5-(5) Distribution of clinical signs before treatment in cases of Group V

Table 6 Distribution of strains isolated before DL-8280 treatment 4) SATO, K.; Y. MATSUURA, M. INOUE, T. UNE, Y. OSADA, H. OGAWA & S. MITSURASHI: In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicr. Agents & Chemoth. 22: 548-553, 1982

Fig. 1-(1) Susceptibility of E. coli isolated before M-8280 treatment Fig. 2-(1) Susceptibility of gram rods except E. coli iso fore DL-8280 treatment Fig. 1-(2) Susceptibility of E. coil isolated before DL-8280 treatment Fig. 2-(2) Susceptibility of gram rods except E. coli ieola fore DL-8280 treatment

Fig. 3-(1) Susceptibility of grain positive cocci isolated before DL-8280 treatment Fig. 4-(1) Correlograma of MIC between DL-8280 and NFLX, PPA and NA: E. coil Fig. 3-(2) Susceptibility of gram positive cocci isolated before DL-8280 treatment

Fig. 4-(2) Correlograma of MIC between DL-8280 and NFLX, PPA and NA: S. fascalis Fig. 4-(3) Corr.lograms of MIC between DL-8280 and NFLX, PPA and NA: gram nega

CHEMOTHERAPY FEB. 1984 Table 7-(2) Bacteriological response to DL-8280 in acute simple cystitis fitting for criteria of UTI committee (78 cases) Table 842) Bacteriological response of Dli-8280 in acute simple cystitis unfitting for criteria of UTI committee (93 cases) -Group I: 3rd or 4th day judgement- * Regardless of bacterial count * Regardless of bacterial count Poly-microbial infection * Table 8-(1) Overall clinical efficacy of DL-8280 in acute simple cystitis unfitting for criteria of UTI committee Group - I: 3rd or 4th day judgement-

Table 9 Results of DL-8280 treatment 3rd or 4th day judgement- - Table 11-(1) Bacteriological response of DL-8280 in Group II (23 cases) -3 rd or 4th day judgement- Table 10 Relation of judgements between the original and UTI committee's criteria -3rd or 4th day judgement- Regardless of bacterial count Poly-microbial infection

Table 11-(2) Bacteriological response of DL-8280 in Group III (11 cases) -3rd or 4th day judgement- Table 12 Bacteriological response of DL-8280 in all cases (131 cases) - 3rd or 4th day judgement- Strains* appearing after treatment Regardless of bacterial count Table 11-(3) Bacteriological response of DL-8280 in Group IV (4 cases) - 3rd or 4th day judgement- Strains* appearing after treatment Strains* appearing after treatment Regardless of bacterial count Poly-microbial infection Regardless of bacterial count Poly-microbial infection

Table 13 Side effects Incidence of side effects: 10/167 (6.0%) Table 14 MIC50 and MICH values of E. coli, gram positive cocci and other gram negative rods isolated before DL-8280 treatment

COMPARATIVE STUDIES ON CLINICAL EFFICACY OF DL-8280 (100 MG/DAY, 3 DAYS TREATMENT) IN VARIOUS TYPES OF FEMALE ACUTE SIMPLE CYSTITIS YOSHIAKI KUMAMOTO, SHIGERU SAKAI, TSUGUO UMEHARA and Department of Urology, Sapporo Medical College TAKAOKI HIROSI SHOGO SHIMAMURA Department of Urology, Sapporo Teishin Hospital TAKAHIRO TAMIYA, KEIJI TAKATSUKA and SHINICHI MIYAMOTO Department of Urology, Sunagawa Municipal Hospital AKIO HONMA and TATSUO AOYAMA Department of Urology, Japan Red Cross Asahikawa Hospital SEIJI FURUYA and EIJI YOKOYAMA Department of Urology, Japan Red Cross Kitami Hospital CHOSHO ENATSU Department of Urology, Tomakomai Oji General Hospital HITOSHI TANDA and SHUJI KATO Department of Urology, Higashi Sapporo Sanjukai Hospital5 TSUNEAKI TORII and MASATAKA FUJITA Department of Urology, Hakodate Goryokaku Hospital KATSUYUKI MITOBE and AKIRA NISHIO Department of Urology, Sakata Municipal Hospital DL-8280, a new pyridone-carboxylic acid type synthetic antimicrobial agent for oral use, was studied fundamentally and clinically and the following conclusions were obtained. 1) The MICs of DL-8280 against clinical isolates were determined. The MICs against 80% of GNR and 30% of GPC were 0.10 pg/ml and less than 0.39 j g/ml, respectively. 2) The urinary concentration during 22-24 hours after a single oral administration at the dose of 100 mg was over 10 Đg/ml and this result suggested DL-8280 was the long-acting drug. 3) Clinical effect and side effect in female patients with acute simple cystitis including the urethral syndrome treated with 100 mg for 3-17 days orally were evaluated. A new original criteria was established for judgement of cases unfitting for criteria of UTI committee. 4) The clinical response in 78 female patients with acute simple cystitis fitting for criteria of UTI committee was excellent in 64 cases, moderate in 14 cases, and clinical efficacy rate was 100%. 5) All cases were divided to group I, II, III, IV and V and therapeutic effect was evaluated in each group. No significant difference in clinical efficacy was observed among all groups, except cases having only subjective symptoms group V by the new original criteria. 6) As to side effects, eruption, itching, lip swelling and gastrointestinal disturbance were observed in 10 cases and rate of appearance was 6.0%. But those were not severe.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック